GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Stoke Therapeutics STOK · USD

Health Care · US listing · 🇺🇸 United States

Compare

27.71

+4.41%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$184.4m

FY2017FY2025

Net income

−$6.9m

FY2017FY2025

Free cash flow

$44.9m

FY2017FY2025

Shareholders' equity

$352.5m

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue$184.4m$36.6m$8.8m$12.4m$3.0m————
Gross profit$184.4m$36.6m$8.8m$12.4m−$2.2m−$1.9m−$450,000−$214,000−$113,000
Research and development$137.9m$89.1m$82.2m$77.8m$54.2m$32.2m$23.8m$8.4m$3.6m
Operating income−$20.6m−$101.4m−$114.8m−$104.4m−$86.1m−$53.0m−$35.7m−$12.8m−$5.6m
Net income−$6.9m−$89.0m−$104.7m−$93.1m−$84.7m−$50.6m−$28.5m−$12.5m−$5.6m
Diluted earnings per share-0.12-1.56-2.33-2.36-2.30-1.44-1.13-0.53-0.24

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$418.4m$271.6m$228.3m$256.1m$238.9m$297.9m$228.8m$107.5m$2.4m
Cash and short-term investments$284.7m$216.9m$201.4m$229.6m$219.8m$287.3m$222.5m$105.4m$1.8m
Total liabilities$66.0m$42.5m$68.8m$71.2m$21.1m$11.8m$4.3m$2.5m$3.7m
Debt$3.0m————————
Shareholders' equity$352.5m$229.0m$159.6m$184.8m$217.8m$286.1m$224.4m$105.1m−$1.3m
Shares outstanding58m57m45m39m37m35m25m24m24m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations$45.6m−$86.9m−$81.1m−$31.9m−$66.9m−$42.2m−$31.1m−$11.0m−$5.4m
Capital spending−$670,000−$203,000−$1.6m−$4.0m−$1.2m−$1.1m−$1.6m−$935,000−$113,000
Free cash flow$44.9m−$87.1m−$82.7m−$35.8m−$68.1m−$43.3m−$32.7m−$11.9m−$5.5m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$9.3m$6.2m$1.4m$10.6m$13.8m$158.6m$22.6m$4.9m
Gross profit$8.2m$5.2m$347,000$9.6m$13.8m$158.6m$22.6m$4.9m
Operating income−$65.4m−$53.4m−$61.4m−$43.1m−$27.3m$111.2m−$13.7m−$30.0m
Net income−$61.6m−$50.0m−$57.9m−$38.3m−$23.5m$112.9m−$10.5m−$26.4m
Diluted earnings per share-0.93-0.76-0.99-0.66-0.401.93-0.18-0.46
Cash from operations−$56.0m−$60.0m−$30.0m−$30.0m−$25.0m$131.0m−$23.0m−$21.0m
Capital spending−$1.0m———————
Free cash flow−$57.0m———————
Total assets$394.0m$443.3m$418.4m$360.3m$384.5m$406.9m$271.6m$293.3m
Cash and short-term investments$292.8m$343.5m$284.7m$248.3m$247.7m$357.3m$216.9m$239.2m
Debt$1.8m$2.4m$3.0m$2.9m$2.3m$2.4m$2.3m$2.3m
Shareholders' equity$345.5m$394.9m$352.5m$308.1m$334.9m$350.1m$229.0m$232.1m

Financial ratios

Data as of 31 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin100.0%100.0%100.0%100.0%-74.3%—
Operating margin-3.7%-243.4%-1192.5%-841.2%-2868.8%—
Net margin-3.7%-243.4%-1192.5%-750.6%-2823.7%—
Return on equity-2.0%-38.9%-65.6%-50.4%-38.9%-17.7%
Return on assets-1.6%-32.8%-45.9%-36.4%-35.5%-17.0%
Free cash flow yield3.0%-5.8%-6.7%-2.7%-6.8%-4.5%
Revenue growth404.5%316.3%-29.2%313.5%——
Earnings growth-92.3%-15.0%12.4%9.9%67.4%77.4%
Current ratio5.28x5.81x6.99x7.77x13.37x25.73x
Debt to equity0.01x0.01x0.01x0.01x0.01x0.00x
Equity ratio84.2%84.3%69.9%72.2%91.2%96.0%
Interest coverage-765.00x-7.04x-10.57x-33.43x-717.21x—
R&D as a share of sales74.8%243.8%936.6%627.5%1805.6%—
Buybacks as a share of market value-2.4%-26.8%-14.0%-7.1%-5.0%-38.4%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue145.9%——
Operating income-41.8%-17.2%—
Net income-58.0%-32.9%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin100.0%100.0%——

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings-269.2-7.1-2.3-3.9-10.4-42.9-25.2
Price to sales10.117.226.929.3294.6——

Market value over time

28 Jun 2019 to 30 Oct 2026, in USD

$29.2m$1.74bn

Share price return

Finished calendar years

2025202420232022202120202019
Return187%113%-36%-58%-68%108%15%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.